The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...